-
1.
公开(公告)号:US20180002435A1
公开(公告)日:2018-01-04
申请号:US15546630
申请日:2016-01-25
Applicant: Cellectis , RINAT NEUROSCIENCE CORPORATION
Inventor: Barbara Johnson SASU , Arvind RAJPAL , Philippe DUCHATEAU , Alexandre JUILLERAT , Julien VALTON
IPC: C07K16/28 , C07K14/705 , G01N15/10 , G01N15/14 , C12N5/0783 , C07K14/725 , G01N15/00
CPC classification number: C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N5/0093 , C12N5/0636 , C12N5/0638 , C12N2510/00 , G01N15/1031 , G01N15/14 , G01N2015/008 , G01N2015/1006 , G01N2015/1081 , G01N2015/149
Abstract: A polypeptide encoding a chimeric antigen receptor (CAR) comprising at least one extracellular binding domain that comprises a scFv formed by at least a VH chain and a VL chain specific to an antigen, wherein said extracellular binding domain comprises at least one mAb-specific epitope.
-
公开(公告)号:US20180051089A1
公开(公告)日:2018-02-22
申请号:US15546623
申请日:2016-01-25
Applicant: Cellectis
Inventor: Roman GALETTO , Barbara Johnson SASU , Arvind RAJPAL , Philippe DUCHATEAU , Alexandre JUILLERAT , Julien VALTON , Mathieu SIMON
IPC: C07K16/28 , A61K35/17 , A61K39/00 , C07K14/725 , C07K16/30 , C12N5/00 , C12N5/0783
CPC classification number: C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N5/0093 , C12N5/0636 , C12N5/0638 , C12N2510/00 , G01N15/1031 , G01N15/14 , G01N2015/008 , G01N2015/1006 , G01N2015/1081 , G01N2015/149
Abstract: The present invention relates to a TCR KO—or TCR KO and dCK KO—engineered immune cells expressing a Chimeric Antigen Receptors (CAR) specific for CD123 that is a recombinant chimeric protein able to redirect immune cell specificity and reactivity toward CD123-expressing cells, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CD123 CARs are particularly suited for treating relapse refractory AML and blastic plasmacytoid dendritic cell neoplasm and for use as a treatment before bone marrow transplantation.
-
3.
公开(公告)号:US20240228636A1
公开(公告)日:2024-07-11
申请号:US18481797
申请日:2023-10-05
Applicant: Cellectis , Allogene Therapeutics, Inc.
Inventor: Barbara Johnson SASU , Arvind RAJPAL , Philippe DUCHATEAU , Alexandre JUILLERAT , Julien VALTON
IPC: C07K16/28 , A61K35/17 , A61K39/00 , A61K39/395 , C07K14/705 , C07K14/725 , C07K14/735 , C07K16/30 , C12N5/00 , C12N5/0783 , G01N15/01 , G01N15/10 , G01N15/1031 , G01N15/14 , G01N15/149
CPC classification number: C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/001176 , A61K39/39558 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C12N5/0093 , C12N5/0636 , C12N5/0638 , G01N15/1031 , G01N15/14 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N2510/00 , G01N2015/016 , G01N2015/1006 , G01N2015/1028 , G01N15/149
Abstract: A polypeptide encoding a chimeric antigen receptor (CAR) comprising at least one extracellular binding domain that comprises a scFv formed by at least a VH chain and a VL chain specific to an antigen, wherein said extracellular binding domain comprises at least one mAb-specific epitope.
-
-